Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy With Imperial College London Research Collaboration
17.1.2022 14:37:00 EET | Business Wire | Press release
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine.
This long-term research collaboration, which combines the long-standing expertise of Stallergenes Greer in AIT with the prestigious research capabilities of Imperial College London, aims to push the boundaries of allergic patient care by identifying biomarkers of AIT efficacy and expanding the knowledge of the pathophysiology of allergic diseases and their treatment with AIT.
“We are thrilled about this collaboration with Imperial College London which will contribute to both deciphering the mode of action of AIT and identifying key markers that can be used in the routine practice of allergology for the benefit of patients and healthcare practitioners. Based on the understanding of specific phenotypes and the responses of patients with allergies, allergologists will be able to tailor treatment modalities with the right dosing at the right time for each individual. This underscores our commitment to advancing precision medicine for allergy sufferers”, stated Amer Jaber, Executive VP Operations Europe and International and President of Stallergenes SAS.
“This research collaboration is a remarkable opportunity for a fruitful partnership between Imperial College London, a pioneer and world-leading university in the biomarker field, and Stallergenes Greer. It will build on the recent advances of biomarker research to further develop precision medicine in AIT for the benefit of patients with allergic diseases,” said Dr Mohamed Shamji, Head of the Immunomodulation and Tolerance Group, Imperial College London.
The results of this research collaboration will be shared in international congresses and peer review publications.
About Allergen Immunotherapy
Allergies are the most prevalent and fastest growing chronic diseases in the industrialised world, affecting over one billion people worldwide. Allergen immunotherapy uniquely alters the natural course of respiratory allergies. It is the only therapeutic class capable of modifying disease progression and potentially preventing the onset of the disease by inducing tolerance in the immune system.
About Stallergenes Greer
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
For more information, visit: www.stallergenesgreer.com
About Imperial College London
Imperial College London is one of the world's leading universities. The College's 20,000 students and 8,000 staff are working to solve the biggest challenges in science, medicine, engineering, and business. Imperial is University of the Year 2022 in the Times and Sunday Times Good University Guide. It is the world’s fifth most international university, according to Times Higher Education, with academic ties to more than 150 countries. Reuters named the College as the UK's most innovative university because of its exceptional entrepreneurial culture and ties to industry.
Imperial staff, students and alumni are working round-the-clock to combat COVID-19. Imperial has nearly two thousand key workers, and is at the forefront of coronavirus epidemiology, virology, vaccine development and diagnostics. More than one thousand Imperial staff and students are volunteering to support the NHS.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220117005222/en/
Contact information
Stallergenes Greer
Catherine Kress
Head of communications
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Adds Collaborating Firm in Uzbekistan20.10.2026 16:30:00 EEST | Press release
Andersen Consulting expands its cybersecurity and business transformation capabilities through a Collaboration Agreement with Algoruni, a consulting firm based in Uzbekistan. Algoruni advises organizations on building cyber resilience, while addressing broader management, regulatory, and sustainability priorities. Operating out of Tashkent, the firm’s services span cybersecurity strategy and data protection, corporate governance and operational improvement, and ESG strategy and reporting, with an emphasis on practical solutions tailored to each client’s circumstances. “Every organization faces a different combination of risks and opportunities, which is why we believe effective solutions must start with the realities of the business,” said Alisher Zaynutdinov, managing director of Algoruni. “Becoming a collaborating firm of Andersen Consulting allows us to pair this approach with broader international resources and perspectives, giving us new ways to help clients turn complex challenge
International AI Strategist and Author Katie King to Keynote IAMPHENOM Europe 202620.10.2026 16:30:00 EEST | Press release
Phenom, the leader in applied AI built to redesign work operations for hiring faster, developing better and retaining longer, announced Katie King, an internationally recognised AI strategist, author and adviser on the future of work, as a keynote speaker at IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. Phenom also unveiled the conference agenda, which centres on the decisions European HR leaders face right now: turning AI, agents and automation into business outcomes, deploying tech with a compliant-first approach, and redesigning roles and skills for the future workforce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020028392/en/ Phenom announced Katie King, an internationally recognised AI strategist, author and adviser on the future of work, as a keynote speaker at IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. Phenom also unveiled the conference agenda, which centres on the
Inaugural Future Health Impact Challenge Documentary Released as Expressions of Interest Open for Second Challenge20.10.2026 16:26:00 EEST | Press release
Future Health – A Global Initiative by Abu Dhabi today premiered a documentary film about the inaugural Future Health Impact Challenge during the first day of the Abu Dhabi Future Health Summit. The film’s global launch, alongside the announcement of the second Challenge connects the Challenge’s initial results with its next phase with Expressions of Interest now open for the second edition. Delivered in collaboration with MIT Solve, the inaugural Impact Challenge demonstrates the transformative power of innovative solutions that accelerate the shift from reactive to anticipatory healthcare systems. With scenes filmed in Kigali, Medellín, São Paulo, Boston, and Abu Dhabi, the film shares personal commentary from the founders, local perspectives of the solutions in action, and insight from Future Health and MIT Solve. It follows the winner and two distinguished finalists as they turn signals from frontline consultations, mosquito surveillance, and routine blood tests into information th
WETEX 2026 attracts 60 sponsoring institutions and companies from the UAE and abroad20.10.2026 16:19:00 EEST | Press release
Dubai Electricity and Water Authority (DEWA) is organising the 28th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 20 to 22 October 2026 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020867659/en/ WETEX 2026 attracts 60 sponsoring institutions and companies from the UAE and abroad (Graphic: AETOSWire) “WETEX reflects the forward-looking vision of His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, and His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, to leverage innovation and advanced global technologies, including digital transformation, artificial intelligence (AI) and smart infrastructure, to strengthen the sustainability and resilience of the water and energy sectors while encouraging climate action,” said HE Saeed Mohammed Al Tayer, MD & CEO of DEWA and Founder and
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 202620.10.2026 16:02:00 EEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The studies span Guardant's cancer portfolio, including tissue-free minimal residual disease (MRD) surveillance, treatment response, and resistance research. Significant studies were conducted independently by industry collaborators, academic institutions, and Guardant’s public-private partners using the company’s technologies and/or real-world data, underscoring the wide adoption of its platform across the research community. “At ESMO, we will showcase how InfinityAI is advancing our portfolio, strengthening the clinic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom